Janssen Search
Search results
Christopher Cutie, M.D.
CHRISTOPHER CUTIE, M.D. Vice President Disease Area Stronghold Leader Bladder Cancer Christopher Cutie, M.D., is Vice President, Disease Area Stronghold (DAS) Leader, Bladder Cancer, in the Oncology Therapeutic Area at Janssen Research & Development, ...
The Maturation of Digital Technologies
The Maturation of Digital Technologies Oct 13, 2016 In a Q&A with Clinical Leader magazine, Dmitri Talantov, M.D., R&D Operations Innovation Medical Leader, Janssen Research & Development, LLC, discussed the maturation of digital technologies ...
Oncology Discovery & Early Development
Discovery and Early Development “We focus our deep expertise and understanding of disease biology and scientific innovation on specific tumor types with the greatest need for new treatment options.” Jeff Infante, M.D. Vice President, Oncology Early ...
Remo Colarusso
Remo Colarusso Vice President Janssen Supply Chain Remo Colarusso is Vice President, Janssen Supply Chain (JSC) at Johnson & Johnson. In this capacity, Remo is responsible for the global manufacturing and supply management of all J&J ...
Recognizing World Arthritis Day 2017
Recognizing World Arthritis Day 2017 For more than three decades, Janssen Immunology has been focused on innovating for patients, because we understand the impact rheumatic diseases have on individuals, and their families, friends and loved ones. The ...
An Update on Our Vaccine Candidate to Prevent COVID-19
An Update on Our Vaccine Candidate to Prevent COVID-19 On July 21, I was pleased to represent Johnson & Johnson at a hearing before the Oversight and Investigations Subcommittee of the U.S. House Energy & Commerce Committee, to update the ...
Carrie Brodmerkel, Ph.D.
CARRIE BRODMERKEL, Ph.D. PORTFOLIO LEADER JANSSEN BIOTHERAPEUTICS Carrie Brodmerkel, Ph.D. is Portfolio Leader for the Janssen BioTherapeutics (JBIO), Janssen Research & Development organization. In this role, Carrie oversees the strategic direction ...
Clinical Trials
Janssen Clinical Innovation Janssen is striving to develop and implement new approaches to improve the clinical trial process for all stakeholders: patients, trial sites/investigators and the healthcare industry at large. Janssen Clinical Innovation (JCI) ...
John Gerecitano, M.D., Ph.D.
JOHN GERECITANO, M.D., PH.D. GLOBAL MEDICAL HEAD LYMPHOMA/LEUKEMIA DISEASE AREA LEADER ONCOLOGY RESEARCH & DEVELOPMENT JOHNSON & JOHNSON INNOVATIVE MEDICINE John Gerecitano, M.D., Ph.D. is the Global Medical Head of the Lymphoma/Leukemia Disease ...
New Research Platforms
Three New Research Platforms Focused on Redefining Healthcare Article Type: World Without Disease Accelerator Disease Interception Accelerator In early 2015, Janssen Research & Development launched three new research platforms that focus on disease ...